Navigation Links
Barr Reports First Quarter 2008 GAAP Earnings of $0.21 Per Share; Adjusted Earnings of $0.57 Per Share
Date:5/8/2008

pany had $52 million of long-term marketable securities at March 31, 2008.

EBITDA

Earnings before interest, taxes, depreciation and amortization (EBITDA) for the first quarter of 2008 totaled $153 million, compared to $158 million in the prior year period. Please see the EBITDA reconciliation table at the end of this press release.

Sanctura(R) Payment from Allergan, Inc.

On May 5, 2008, the Company entered into an agreement with a subsidiary of Allergan, Inc. related to Allergan's Sanctura(R) product that PLIVA divested in 2005 to Esprit Pharma, which has since been acquired by Allergan. Under the terms of this agreement, Allergan paid Barr $53 million, extinguishing any future payment obligations related to Sanctura(R). Barr will record the $53 million in the Company's second quarter 2008 earnings.

Revised 2008 Financial Outlook

The Company is revising its adjusted earnings per fully diluted share guidance for 2008 to be in the range of approximately $2.75 - $3.05, down from the $3.05 -$3.35 range that the Company provided in February 2008. The decrease in the range is the result of several factors, including the Company's results for the first quarter of 2008, which were lower than it expected, lower than anticipated U.S. generic revenues due to timing of new product launches, lower than anticipated Plan B revenues, lower gross profit margins due to a shift in product mix, and increased investment in R&D. The impact of these factors will not be fully offset by contributions from the Company's expected launch of generic Yasmin (drospirenone and ethinyl estradiol) in mid-2008. The Company's adjusted earnings guidance excludes the $53 million one-time payment from Allergan related to the Sanctura product.

Based on the factors listed above, the Company expects total revenues for 2008 to be in the range of $2.7 - $2.8 billion, including total product sales in the range of $2.5 - $2.6 billion. Revenue and product sales es
'/>"/>

SOURCE Barr Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. BioCryst Reports First Quarter 2008 Financial Results and Clinical Update
2. Dendreon Reports First Quarter 2008 Financial Results
3. Nutrition 21 Reports Fiscal Third Quarter 2008 Financial Results
4. Volcano Reports 24 Percent Increase in First Quarter Revenues; IVUS Disposable Revenues Increase 30 Percent
5. Oncothyreon Reports First Quarter 2008 Financial Results
6. iCAD Reports First Quarter 2008 Financial Results
7. AEterna Zentaris Reports First Quarter 2008 Financial and Operating Results
8. American Oriental Bioengineering Reports First Quarter 2008 Financial Results
9. Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update
10. Onyx Pharmaceuticals Reports 2008 First Quarter Results
11. AtriCure Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... Mass. , July 30, 2014 /PRNewswire/ ... ), a biotechnology company focused on discovering, ... unmet medical needs using RNA-targeted technologies, today ... (RXI-109-1402) with RXI-109, for the reduction of ... revision surgery, has been initiated. ...
(Date:7/30/2014)... Diego, CA (PRWEB) July 30, 2014 ... contract from the U.S. Environmental Protection Agency (EPA). ... expertise in developmental toxicity models, including tests designed ... neuron formation and the formation of connections between ... Inhibition of neurodifferentiation and synapse formation by environmental ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 LayerBio, Inc., ... completion of its first round of seed financing from ... enable preliminary efforts to develop a novel sustained-release product ... of our investors and their commitment to this important ... LayerBio. "Ophthalmology is one of many areas in which ...
(Date:7/29/2014)... hurdled a number of significant technological challenges in ... technology originally created for the James Webb Space ... Harvey Moseley, a scientist at NASA,s Goddard Space ... electrostatically actuated microshutter arrays that is, those ... as functional as the current technology,s magnetically activated ...
Breaking Biology Technology:RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 2RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 4RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 5U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 2U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 3Revolutionary microshutter technology hurdles significant challenges 2Revolutionary microshutter technology hurdles significant challenges 3Revolutionary microshutter technology hurdles significant challenges 4
... 30 Rib-X Pharmaceuticals, Inc., a development stage company focused ... treatment of antibiotic resistant infections, announced today that Russell Greig, ... the Company,s Board of Directors. Rib-X,s board now consists ... pleased that Russell Greig has joined the Rib-X Board of ...
... ... Northern Irish packaging machinery manufacturer, Sepha Ltd. is breaking into one of ... testing and de-blistering machines for the first time there ... Ahead of its presence at Interphex, Sepha has already received ...
... /PRNewswire-Asia/ -- Pharmaxis (ASX: PXS; Nasdaq: PXSL ),today ... Plan which,closed on 24 June 2009. Shareholders of the ... of shares each at the $2.35 price,paid by institutional investors ... total of 1,584 shareholders participated in the plan under which ...
Cached Biology Technology:Rib-X Pharmaceuticals, Inc. Appoints Dr. Russell Greig to Board of Directors 2Rib-X Pharmaceuticals, Inc. Appoints Dr. Russell Greig to Board of Directors 3Asia Debut for Money-Saving Pharma-Packaging Machines from Ireland 2Asia Debut for Money-Saving Pharma-Packaging Machines from Ireland 3Pharmaxis Closes Share Purchase Plan 2
(Date:7/30/2014)... could be as simple as inserting a medicated, disappearing ... Washington bioengineers have discovered a potentially faster way to ... HIV. Their method spins the drug into silk-like fibers ... higher doses of the drug than possible with other ... could offer women a potentially more effective, discreet way ...
(Date:7/30/2014)... figured out how to create colors, nature had already ... of many different hues, for example. Now scientists are ... friendly way to make colored plastics. Their paper on ... materials rather than dyes, to produce color appears ... N. Asger Mortensen, Anders Kristensen and colleagues point out ...
(Date:7/30/2014)... awarded the Scientific Committee on Antarctic Research,s (SCAR) ... SCAR, an inter-disciplinary international science body, initiates, develops ... the Antarctic region, and on the role of ... organisation also provides scientific advice about Antarctica to ... region. , The medal is open internationally to ...
Breaking Biology News(10 mins):Dissolvable fabric loaded with medicine might offer faster protection against HIV 2Dissolvable fabric loaded with medicine might offer faster protection against HIV 3
... CORVALLIS, Ore. An international group of more than 30 ... their contribution to the health of the world,s oceans, which ... identified food provision, tourism and recreation as leading concerns. ... each nation on a 0-100 scale in 10 separate categories ...
... on fetal growth have consistently demonstrated deficits that persist ... human studies have been inconsistent. A new study ... on growth and body composition throughout childhood has found ... age, as well as a delay in weight gain ...
... cells has provided scientists at Dana-Farber Cancer Institute and the ... entirely new class of genes that may serve as an ... in the Aug. 17 issue of the journal Cell ... of which had previously been identified as potential targets for ...
Cached Biology News:Rating of ocean health shows 'room for improvement' 2Tracking the effects of prenatal alcohol exposure through to 9 years of age 2Tracking the effects of prenatal alcohol exposure through to 9 years of age 3'CYCLOPS' genes may serve as an Achilles' heel in tumor cells 2'CYCLOPS' genes may serve as an Achilles' heel in tumor cells 3
... is most widely used in combination ... differentially stain nucleic acids following polyacrylamide ... solution, Pyronin Y stains RNA red, ... Chem comp: Dye content ...
... The loxP-cm-loxP cassette is ... prokaryotic cells. The prokaryotic promoter ... resistance is a slightly modified version ... higher transcription efficiency than the generally ...
... Agencourt AMPure is a ... that requires no sample transfer, ... efficiently purifies small and large ... or 384-well microplates. Agencourt AMPure ...
... is a magnetic bead-based PCR ... sample transfer, centrifugation or filtration ... and large PCR extension products ... Agencourt AMPure can easily be ...
Biology Products: